Figure 5.

Fuc-liposome-SN38 suppressed tumor growth and prolonged the survival in a peritoneal dissemination model. A) Treatment schedule for the CRC xenograft mouse model. SN38 (1 mg/kg), F0-liposome-SN38 (1 mg/kg), or F50-liposome-SN38 solution (1 mg/kg) was administered via tail vein injection twice a week for three weeks. B) Tumor tissue was prepared on day 22 after the beginning of the treatment. Hematoxylin and eosin staining and CC3 staining in Colo205 tumors are shown. C) Survival rate of the mice treated with SN38 alone, F0-liposome-SN38, and F50-liposome-SN38 in the peritoneal dissemination model. Statistical analysis was performed by log-rank test. *P < .01 compared with NT, SN38, and F0. D) Representative image of Colo205 tumor-bearing mice. On days 15 and 40 after the start of the treatment, luciferase activity was monitored using the IVIS imaging system.